Kaplan Fox Encourages Investors of Flotek Industries, Inc. (NYSE: FTK) to Contact the Firm Before Lead Plaintiff Deadline on October 26, 2026

A securities class action was filed against Flotek Industries over allegations that its reported 10-year, $400 million PREPA-related power-generation contract was canceled and that the company failed to disclose risks to its realization. Wolfpack Research alleged the contract represented approximately 57% of Flotek's backlog, prompting FTK shares to fall $7.17, or 20%, to $28.66 on August 17, 2026. Investors who acquired shares from August 3 through August 14 may seek lead-plaintiff status by October 26, 2026.

Analysis

The actionable issue is not the shareholder suit itself—these filings rarely change enterprise value—but whether the disputed project was embedded in FTK’s revenue, utilization, and working-capital assumptions. A backlog concentration near this scale creates a double hit if the award is not executable: lost future gross profit plus under-absorption of personnel and equipment costs. Until FTK provides counterparty documentation, termination notices, or revised guidance, the equity should trade as a credibility-discounted small-cap rather than on a normalized services multiple.

Over the next days, borrow availability and incremental short-report follow-up matter more than the October legal deadline. The key 1–3 month catalyst is management’s next formal disclosure: confirmation of a binding, financeable contract and mobilization would drive a sharp squeeze; a cancellation, scope reduction, delayed notice-to-proceed, or guidance withdrawal would likely force another leg down because consensus estimates may still capitalize the project. Litigation reserve exposure is secondary and probably immaterial relative to the operating-risk repricing.

The non-obvious risk is customer-concentration contagion across FTK’s broader chemical and production-services valuation: investors may question whether other announced awards have comparable counterparty-credit or execution contingencies. Conversely, the bearish consensus may be overextending if the alleged cancellation reflects a consortium-level financing or procurement delay rather than loss of FTK’s service role; a definitive contract-status filing would be more probative than either the law-firm notice or an uncorroborated research allegation. BAC and ALV have no evident fundamental linkage here and should not be traded on this item.

Key Decisions for Investors

• Maintain or initiate a tactical FTK short only after confirming borrow and liquidity; target a 1–3 month catalyst window around management disclosure/earnings. Size modestly given high squeeze risk in a small-cap name; cover if FTK documents an enforceable notice-to-proceed, identifies funded counterparties, and reaffirms project-linked revenue timing.
• For defined risk, prefer FTK put spreads dated beyond the next earnings/reporting event rather than naked puts: buy an at/near-money put and sell a 20–30% lower strike. The thesis is a second estimate reset, while the short lower strike recognizes that the initial credibility shock may already capture part of the downside.
• Do not treat the class-action filing as an independent short catalyst. Set an alert for any SEC filing that quantifies backlog removal, revised capex/working-capital needs, project mobilization, or customer termination; these disclosures determine whether the revenue-loss thesis is investable.
• If FTK verifies contract enforceability and funding before the next earnings release, close bearish exposure rather than averaging down. A reversal could be violent because the stock’s discount is driven by uncertainty, not a confirmed impairment, and short covering would compound the recovery.